Cancer News

Piqray® approved for the treatment of postmenopausal women with breast cancer (05/29/2019)

The US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer.[1] PIK3CA is the most commonly mutated gene in HR+/HER2- breast cancer; approximately 40% of patients... Continue Reading

Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer (05/06/2019)

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness – increasing patient convenience. Dr. Jackisch M.D. and colleagues reported the results of an open-label, multi-center, international clinical trial to... Continue Reading

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer (04/30/2019)

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer (ESBC).(1) In the United States “dose dense” chemotherapy is considered standard of care for the treatment... Continue Reading

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer (04/08/2019)

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in the Early Breast Cancer Trialists Collaborative Group who evaluated 37,000 women who participated in 26 clinical trials... Continue Reading

Immunotherapy Offers New Hope in Triple Negative Breast Cancer (12/28/2018)

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed cell death ligand 1 (PD-1+) patients.  The results were seen with the PD-L1 drug Tecentriq used in combination with chemotherapy for the treatment of triple negative breast cancer. …

Continue reading "Immunotherapy Offers New Hope in Triple Negative Breast Cancer"

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications (12/21/2018)

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology biosimilar approval in the United States in the past month. Specifically, Herzuma is approved to treat: Adjuvant breast cancer of HER2 overexpressing node positive or node negative (ER/PR negative …

Continue reading "Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications"

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer (12/19/2018)

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started the treatment in the first 30 days after surgery, according to a retrospective study presented at the 2018 San Antonio Breast …

Continue reading "Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer"

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer (12/12/2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine (T-DM1) had improved disease-free survival compared to patients who received adjuvant trastuzumab, according to the results from the phase 3 KATHERINE trial. Previously reported …

Continue reading "Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer"

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors (12/11/2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4–8. Hot flashes, a common symptom of menopause, can be more severe in breast …

Continue reading "Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors"

Choice of surgery may affect quality of life for young breast cancer survivors (12/10/2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber/Brigham and Women’s Cancer Center. The findings, presented at the San Antonio Breast Cancer Symposium, underscore the importance of counseling patients about the …

Continue reading "Choice of surgery may affect quality of life for young breast cancer survivors"